Sterne Agee CRT Reiterates Buy on Under Armour (UA) Following Investor Day
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Canaccord Genuity Reiterates Buy on Under Armour (UA) Following Investor Day
September 17, 2015 9:15 AM EDTCanaccord Genuity reiterated a Buy rating and $105.00 price target on Under Armour, Inc. (NYSE: UA) following the company's investor day. UA released 2018 targets that call for $7.5B in revenue and $800M in EBIT. It also puts UA within striking distance of $10B in 2019.
Analyst Camilo Lyon commented, "It is well... More
Cowen Raises Price Target on Under Armour (UA) to $120 Following Investor Day
September 17, 2015 8:44 AM EDTCowen reiterated an Outperform rating on Under Armour, Inc. (NYSE: UA), and raised the price target to $120.00 (from $112.00), following the company's investor day. Management initiated FY18 revenue and operating income targets of $7.5B and $800MM respectively.
Analyst John Kernan commented, "UA issued revenue... More
Piper Jaffray Remains Bullish on Under Armour (UA) Following Analyst Day
September 17, 2015 6:46 AM EDTPiper Jaffray maintained an Overweight rating and $1133.00 price target on Under Armour, Inc. (NYSE: UA) following the company's analyst day. UA set its 2018 targets of $7.5B in sales and $800M in operating income.
Analyst Erinn Murphy commented, "We reiterate our OW rating on UA following the company's well-attended... More
Under Armour (UA), Stephen Curry Announce Extension of Partnership Through 2024
September 16, 2015 4:55 PM EDTStephen Curry made a surprise appearance at Under Armour's (NYSE: UA) Global Headquarters in Baltimore today to join Founder and CEO Kevin Plank in announcing the extension of his partnership with the brand through 2024. In 2015, Curry established himself as one of the game's best players, capturing the league MVP award and leading the Golden State Warriors to their first championship in 40 years.
"Stephen is a once-in-a-generation talent and has unprecedented influence on the game of basketball," said Adam Peake, EVP, Global Marketing. "His work ethic, uncompromising self-belief, and commitment to the community are... More
Under Armour (UA) Targets 2018 Revenue of $7.5B
September 16, 2015 4:34 PM EDTUnder Armour, Inc. (NYSE: UA) today unveiled the next chapter of its long-term growth story at its biennial Investor Day meeting, highlighted by a 2018 net revenues target of $7.5 billion, representing a 25% compounded annual growth rate from $3.1 billion in net revenues in 2014.
Kevin Plank, Chairman and Chief Executive Officer, stated, "For nearly 20 years, the Under Armour brand has been built on the promise to make all athletes better. Leveraging our foundation in innovation and enhancing the connectivity of our brand with consumers through Connected Fitness, we are better positioned than ever before to... More
Notable 52-Week Highs and Lows 9/16: (ITCI) (COLL) (UA) High; (GBSN) (XNPT) (NR) Low
September 16, 2015 3:47 PM EDT52-Week High:Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) $49.72. Intra-Cellular Therapies ramping after it announced positive results from the first Phase 3 clinical trial of ITI-007 for the treatment of patients with schizophrenia. In this trial, once-daily ITI-007 60 mg met the primary endpoint and demonstrated antipsychotic efficacy with statistically significant superiority over placebo at Week 4 (study endpoint) as measured by the change from baseline on the Positive and Negative Syndrome Scale (PANSS) total score (p=0.022).
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) $23.45.... More
Sterne Agee CRT Reiterates Buy on Under Armour (UA) Following Investor Day
September 16, 2015 1:05 PM EDTSterne Agee CRT reiterated a Buy rating and $120.00 price target on Under Armour, Inc. (NYSE: UA) following its investor day in Baltimore. Management set 2018 goals of $7.5B in revenues and $800M in operating income. This indicates a 2018 EPS goal of ~$2.20. Full-year 2015 revenue is... More
Deutsche Bank Bullish on Nike's (NKE) Opportunity in China Despite Macro Risks
September 16, 2015 9:50 AM EDTDeutsche Bank maintained a Buy rating on Nike (NYSE: NKE) and raised its price target to $125.00 (from $120.00). Despite macro risks, analyst Dave Weiner is positive on China's s athletic sector and thinks it is the next big thing for Nike and Under Armour... More

